Reference entry
AOD-9604 (hGH Fragment 176-191)
Modified hGH Fragment · Fat Loss Peptide
Overview
AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone. Unlike full GH, it does not increase IGF-1, affect glucose metabolism, or cause insulin resistance.
Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation, without binding to the GH receptor. Does not affect glucose metabolism or increase IGF-1 levels.
Increases fat oxidation, plasma glycerol levels, and reduces body weight in obese models without affecting glucose metabolism.
Reduces fat synthesis and storage in adipose tissue.
Does not cause hyperglycemia, reduce insulin secretion, or increase insulin resistance.
Mechanism
AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone. Unlike full GH, it does not increase IGF-1, affect glucose metabolism, or cause insulin resistance.
Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation, without binding to the GH receptor. Does not affect glucose metabolism or increase IGF-1 levels.
Increases fat oxidation, plasma glycerol levels, and reduces body weight in obese models without affecting glucose metabolism.
Research areas
- AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone. Unlike full GH, it does not increase IGF-1, affect glucose metabolism, or cause insulin resistance.
- Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation, without binding to the GH receptor. Does not affect glucose metabolism or increase IGF-1 levels.
- Increases fat oxidation, plasma glycerol levels, and reduces body weight in obese models without affecting glucose metabolism.
- Reduces fat synthesis and storage in adipose tissue.
- Does not cause hyperglycemia, reduce insulin secretion, or increase insulin resistance.
Research notes
- Generally well-tolerated in clinical trials
- Mild injection site reactions possible
- No reported effects on blood glucose or insulin
- Severe injection site reactions or infection signs
- Unusual swelling or persistent redness
References
- pubmed.ncbi.nlm.nih.gov/11713213/
- pubmed.ncbi.nlm.nih.gov/10950816/
- pubmed.ncbi.nlm.nih.gov/11146367/
- pubmed.ncbi.nlm.nih.gov/26275694/
- pubmed.ncbi.nlm.nih.gov/11673763/
Questions
Does AOD-9604 cause blood sugar problems like full human growth hormone?
No. AOD-9604 is a modified hGH fragment that stimulates lipolysis without binding to the GH receptor or affecting glucose metabolism. Unlike full GH which causes hyperglycemia and insulin resistance, AOD-9604 does not increase IGF-1 levels or disrupt glucose homeostasis, making it metabolically safer.
Can AOD-9604 be stacked with semaglutide or other weight loss peptides?
Yes. AOD-9604's lipolytic mechanism complements semaglutide's appetite suppression through completely different pathways. However, combination data is limited. Both are safe separately; combining requires monitoring for additive dehydration/GI effects common with semaglutide.
Is there any cartilage repair evidence for AOD-9604 in humans?
Animal studies show AOD-9604 combined with hyaluronic acid cartilage regeneration in osteoarthritis models. However, this is preclinical; human cartilage repair data doesn't exist. Joint health claims should be considered theoretical unless based on clinical trial data.